BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report)’s stock is going to reverse split on the morning of Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, January 28th.
BriaCell Therapeutics Stock Performance
NASDAQ:BCTX opened at $0.39 on Friday. The company has a 50-day moving average of $0.68 and a 200-day moving average of $0.75. BriaCell Therapeutics has a 52 week low of $0.37 and a 52 week high of $4.61. The company has a market capitalization of $17.02 million, a price-to-earnings ratio of -0.43 and a beta of 1.55.
BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) last posted its quarterly earnings results on Monday, December 16th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). Sell-side analysts forecast that BriaCell Therapeutics will post -1.01 EPS for the current year.
Analyst Ratings Changes
View Our Latest Report on BCTX
Institutional Investors Weigh In On BriaCell Therapeutics
A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned approximately 0.44% of BriaCell Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 15.42% of the company’s stock.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
See Also
- Five stocks we like better than BriaCell Therapeutics
- How to Read Stock Charts for Beginners
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What Are Earnings Reports?
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Health Care Stocks Explained: Why You Might Want to Invest
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
